---

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C.
20549

FORM 10-Q

(Mark One)

[ x ] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
  SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **December 31, 2008**

OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________ to
___________________

Commission file number: **000-52885**

PURE PHARMACEUTICALS CORPORATION(Exact name of Registrant as Specified in Its Charter)

|NEVADA                                           | 45-0476087                       
|------------------------------------------------ | ---------------------------------
|(State or Other Jurisdiction of Incorporation or | (IRS Employer Identification No.)
|Organization)                                    |                                  
|                                                 |                                  
|                                                 |                                  
|P.O. BOX 55, 1594 STONE MILL PARK,               |                                  
|BELLONA, NY                                      | 14415                            
|(Address of Principal Executive Offices)         | (Zip Code)                       

(315) 849-2822(Registrants Telephone Number,
Including Area Code)

_______________________________________________________(Former
Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant: (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.Yes [ x ] No [ ]

Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of large accelerated filer,
accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act. (Check one):

|Large accelerated filer [ ] |                                               | Accelerated filer [ ]          
|--------------------------- | --------------------------------------------- | -------------------------------
|Non-accelerated filer [ ]   | (Do not check if a smaller reporting company) | Smaller reporting company [ x ]

Indicate by check mark whether the registrant is a shell company
  (as defined in Rule 12b-2 of the Exchange Act).
Yes [ x ] No [ ]

---

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS
DURING THE PRECEDING FIVE YEARS

Indicate by check mark whether the registrant has filed all
documents and reports required to be filed by Sections 12, 13 or 15(d) of the
Securities Exchange Act of 1934 subsequent to the distribution of securities
under a plan confirmed by a court.Yes [ ] No [ ]

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the
issuers classes of common stock, as of the latest practicable date.

---

PART 1 FINANCIAL INFORMATION

Item 1. Financial Statements.

PURE PHARMACEUTICAL CORPORATION (A Development Stage
Company)

FINANCIAL STATEMENTS

DECEMBER 31, 2008

---

|PURE PHARMACEUTICAL CORPORATION
|-------------------------------
|(A Development Stage Company)  
|BALANCE SHEETS                 
|(Unaudited)                    

|                                                           |  | December
      31, |   |  | September 30, |  
|---------------------------------------------------------- |  | ------------------ | - |  | ------------- | -
|                                                           |  | 2008               |   |  | 2008          |  
|                                                           |  | - $ -              |   |  | - $ -         |  
|                                                           |  |                    |   |  |               |  
|ASSETS                                                     |  |                    |   |  |               |  
|Current                                                    |  |                    |   |  |               |  
|Cash                                                       |  | 13,224             |   |  | 12,459        |  
|                                                           |  | 13,224             |   |  | 12,459        |  
|                                                           |  |                    |   |  |               |  
|LIABILITIES                                                |  |                    |   |  |               |  
|Current                                                    |  |                    |   |  |               |  
|Accounts payable
      and accrued liabilities             |  | 45,950             |   |  | 46,213        |  
|                                                           |  |                    |   |  |               |  
|Long-term loan                                             |  | 40,800             |   |  | 40,000        |  
|                                                           |  | 86,750             |   |  | 86,213        |  
|                                                           |  |                    |   |  |               |  
|STOCKHOLDERS EQUITY                                       |  |                    |   |  |               |  
|Authorized:                                                |  |                    |   |  |               |  
|100,000,000 common shares with a par value
      of $0.001 |  |                    |   |  |               |  
|Issued and Outstanding:                                    |  |                    |   |  |               |  
|12,600,000 common shares                                   |  |                    |   |  |               |  
|(September 30, 2008  12,600,000)                          |  | 12,600             |   |  | 12,600        |  
|Additional paid up capital                                 |  | 164,200            |   |  | 161,800       |  
|Accumulated comprehensive loss                             |  | 242                |   |  | 271           |  
|Deficit accumulated during the development stage           |  | (250,568           | ) |  | (248,425      | )
|                                                           |  | (73,526            | ) |  | (73,754       | )
|                                                           |  | 13,224             |   |  | 12,459        |  

 See Accompanying Note 

---

|PURE PHARMACEUTICAL CORPORATION
|-------------------------------
|(A Development Stage Company)  
|STATEMENTS OF OPERATIONS       
|(Unaudited)                    

|                           |  |             |   |  |             |   |  | Cumulative     |  
|-------------------------- |  | ----------- | - |  | ----------- | - |  | -------------- | -
|                           |  |             |   |  |             |   |  | from           |  
|                           |  | Three       |   |  | Three       |   |  | September      |  
|                           |  | months      |   |  | months      |   |  | 24, 2004       |  
|                           |  | ended       |   |  | ended       |   |  | (Inception) to |  
|                           |  | December    |   |  | December    |   |  | December 31,   |  
|                           |  | 31, 2008    |   |  | 31, 2007    |   |  | 2008           |  
|                           |  | -
      $ - |   |  | -
      $ - |   |  | -
      $ -    |  
|                           |  |             |   |  |             |   |  |                |  
|Revenue                    |  | 4,000       |   |  | -           |   |  | 16,088         |  
|Cost of
      sales        |  | -           |   |  | -           |   |  | 9,670          |  
|                           |  | 4,000       |   |  | -           |   |  | 6,418          |  
|                           |  |             |   |  |             |   |  |                |  
|Expenses                   |  |             |   |  |             |   |  |                |  
|Financing fees             |  | -           |   |  | -           |   |  | 5,600          |  
|General and administrative |  | 5,343       |   |  | 8,417       |   |  | 245,456        |  
|Interest on long term loan |  | 800         |   |  | -           |   |  | 800            |  
|Write-down of inventory    |  | -           |   |  | -           |   |  | 5,130          |  
|                           |  | 6,143       |   |  | 8,417       |   |  | 256,986        |  
|Net loss                   |  | (2,143      | ) |  | (8,417      | ) |  | (250,568       | )
|                           |  |             |   |  |             |   |  |                |  
|Loss per share  basic and |  |             |   |  |             |   |  |                |  
|diluted                    |  | (0.00       | ) |  | (0.00       | ) |  |                |  
|                           |  |             |   |  |             |   |  |                |  
|Weighted average number    |  |             |   |  |             |   |  |                |  
|of common shares           |  |             |   |  |             |   |  |                |  
|outstanding                |  | 12,600,000  |   |  | 12,600,000  |   |  |                |  

 See Accompanying Note 

---

|PURE PHARMACEUTICAL CORPORATION
|-------------------------------
|(A Development Stage Company)  
|STATEMENTS OF CASH FLOWS       
|(Unaudited)                    

|                                                |  |             |   |  |             |   |  | Cumulative     |  
|----------------------------------------------- |  | ----------- | - |  | ----------- | - |  | -------------- | -
|                                                |  |             |   |  |             |   |  | from           |  
|                                                |  | Three       |   |  | Three       |   |  | September      |  
|                                                |  | months      |   |  | months      |   |  | 24, 2004       |  
|                                                |  | ended       |   |  | ended       |   |  | (Inception) to |  
|                                                |  | December    |   |  | December    |   |  | December 31,   |  
|                                                |  | 31, 2008    |   |  | 31, 2007    |   |  | 2008           |  
|                                                |  | -
      $ - |   |  | -
      $ - |   |  | -
      $ -    |  
|                                                |  |             |   |  |             |   |  |                |  
|Cash Flows From Operating Activities            |  |             |   |  |             |   |  |                |  
|Net loss                                        |  | (2,143      | ) |  | (8,417      | ) |  | (250,568       | )
|Non-cash items:                                 |  |             |   |  |             |   |  |                |  
|Donated capital                                 |  | 2,400       |   |  | 2,400       |   |  | 40,800         |  
|Accrued interest on long term loan              |  | 800         |   |  | -           |   |  | 800            |  
|Write off in inventory                          |  | -           |   |  | -           |   |  | 5,130          |  
|Change in non-cash working capital              |  |             |   |  |             |   |  |                |  
|balances:                                       |  |             |   |  |             |   |  |                |  
|Inventory                                       |  | -           |   |  | -           |   |  | (5,130         | )
|Accounts payable                                |  | (263        | ) |  | 6,000       |   |  | 45,950         |  
|Net cash used in operations                     |  | 794         |   |  | (17         | ) |  | (163,018       | )
|                                                |  |             |   |  |             |   |  |                |  
|Cash Flows From Financing Activities            |  |             |   |  |             |   |  |                |  
|Capital stock issued                            |  | -           |   |  | -           |   |  | 136,000        |  
|Long-term loan                                  |  | -           |   |  | -           |   |  | 40,000         |  
|Net cash provided
      by financing activities |  | -           |   |  | -           |   |  | 176,000        |  
|                                                |  |             |   |  |             |   |  |                |  
|Effect of
      exchange rate changes           |  | (29         | ) |  | -           |   |  | 242            |  
|                                                |  |             |   |  |             |   |  |                |  
|Increase (Decrease) In Cash                     |  | 765         |   |  | (17         | ) |  | 13,224         |  
|                                                |  |             |   |  |             |   |  |                |  
|Cash,
      beginning                           |  | 12,459      |   |  | 28,906      |   |  | -              |  
|Cash, ending                                    |  | 13,224      |   |  | 28,889      |   |  | 13,224         |  
|                                                |  |             |   |  |             |   |  |                |  
|Supplementary Cash Flow                         |  |             |   |  |             |   |  |                |  
|Information:                                    |  |             |   |  |             |   |  |                |  
|Cash paid for:                                  |  |             |   |  |             |   |  |                |  
|Interest                                        |  | -           |   |  | -           |   |  | -              |  
|Income taxes                                    |  | -           |   |  | -           |   |  | -              |  

- See Accompanying Note-

---

|PURE PHARMACEUTICAL CORPORATION 
|--------------------------------
|(A Development Stage Company)   
|                                
|NOTE TO THE FINANCIAL STATEMENTS
|                                
|DECEMBER 31, 2008               
|(Unaudited)                     

|1. | BASIS OF PRESENTATION
|-- | ---------------------

Unaudited Interim Consolidated
Financial Statements

The accompanying unaudited interim
financial statements have been prepared in accordance with generally accepted
accounting principles for interim financial information and in accordance with
the rules and regulations of the Securities and Exchange Commission. They may
not include all information and footnotes required by generally accepted
accounting principles for complete financial statements. However, except as
disclosed herein, there has been no material changes in the information
disclosed in the notes to the financial statements for the year ended September
30, 2008, included in the Companys Form 10-KSB filed with the Securities and
Exchange Commission. The unaudited interim financial statements should be read
in conjunction with those financial statements included in the Form 10-KSB. In
the opinion of Management, all adjustments considered necessary for a fair
presentation, consisting solely of normal recurring adjustments, have been made.
Operating results for the three months ended December 31, 2008 are not
necessarily indicative of the results that may be expected for the year ending
September 30, 2009.

---

Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations.

Forward Looking Statements

In addition to historical information, the following discussion
and other parts of this document may contain forward-looking statements. These
statements relate to future events or our future financial performance. In some
cases, you can identify forward-looking statements by terminology such as "may,"
"will," "should," "expect," "plan," "anticipate," "believe," "estimate,"
"predict," "potential," or "continue," the negative of such terms or other
comparable terminology. These statements are only predictions. The events
described in forward looking statements we make in this Form 10-Q may not occur.
Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results, levels of
activity, performance or achievements. We caution you that these statements are
not guarantees of future performance or events and are subject to a number of
uncertainties risks and other influences, many of which are beyond our control
that may influence the accuracy of the statements and the projections upon which
the statements are based. Moreover, neither we nor any other person assume
responsibility for the accuracy and completeness of the forward-looking
statements. Except as may be required by law, we undertake no obligation to
publicly update any of the forward-looking statements after the date of this
report to conform such statements to actual results or to changes in our
expectations.

Actual results could differ materially from those anticipated
by such forward-looking statements. The following discussion should be read in
conjunction with the financial statements as well as other financial information
appearing elsewhere in this document. Readers are also urged to carefully review
and consider the various disclosures made by us which attempt to advise
interested parties of the factors which affect our business.

Our Business

The Company was formed in order to seek business opportunities
in the area of expertise of the Company's principal stockholder, Mr. Roger
Gordon, being biological and/or medical products for animal use. The Company
principally operated in the field of generic animal health and nutrition
products, specifically medicated feed additives (MFAs). MFAs are used
preventively and therapeutically in animal feed to prevent disease and foster
growth in livestock. In North America, 90% of all feed to animals contain MFAs.
Our intended customers operate in the poultry, swine and cattle markets. The
Company has historically focused its efforts on generic MFAs, as they have come
off patent, therefore making them more economical to register with requisite
regulators in the United States and Canada, with a view to bringing the products
to market.

The Company continued to market a related-party owned MFA,
Oxytetracycline, and are in the exploratory phase of identifying generic MFAs
that it intended to test and register with regulatory authorities with a view to
being granted a DIN or similar authorization to market such MFAs in North
America (henceforth, the identification process). As market dynamics have
undergone significant systemic changes over the past three years with the
emergence of avian flu and the attendant fall in poultry consumption worldwide,
management has had to conduct the identification process with due deliberation.
Furthermore, with the prices of feed, particularly maize, at record high prices,
out intended customers have been hesitant to add to their expenses.

The Company's activities to date have been primarily
organizational in nature and as a result the Company must be considered to be in
its developmental stage. The Company relies solely on the efforts of its
management and director and has no employees, owns few business assets,
technology or real estate and

---

since inception has been primarily involved in developing its
business plan, preliminarily identifying generic MFAs for registration, and
raising initial capital.

Management previously determined to refocus, assess and
identify alternative business strategies due to prolonged high prices of maize
and other inputs and other general economic conditions affecting the business of
the Company.

Recent Developments

Sales have decreased year over year due to the increasing
prices of maize. As a result of the prolonged high prices of inputs and other
general conditions affecting the business of the Company, management determined,
in the prior quarter, to refocus, assess and identify alternative business
strategies. In July 2008, the Company was quoted on the OTC Bulletin Board under
the symbol PCMS.

Results of Operations

Results of Operations for the Period ended December 31,
2008

The Company was able to sell the remainder of its Oxytetracline
MFA and earned $4,000 from its sale in the three months ended December 31, 2008
whereas in the comparable period in 2007 the Company did not earn any revenue.
We incurred operating expenses in the amount of $6,143 for the three months
ended December 31, 2008 compared to $8,417 in the comparable period in 2007. Our
net loss for the three months ended December 31, 2008 was $2,143 and was $8,417
in 2007. The Companys losses stem from the payment of professional fees.

Sales and marketing of the Companys Oxytetracyline and the
process of the company pursuing opportunities in the generic MFAs areas continue
to be very difficult this quarter. Though we sold our remaining inventory at a
fair price, we do not anticipate importing more in the first six months of 2009
as the manufacturer in the Peoples Republic of China is planning to idle
production until the overall economic situation improves. Due to an acute
fluctuation in the price of key ingredients; corn and soybeans; the ability for
producers to manage price pressure is severely challenged. Corn prices had
surged 5 fold in the last 24 months to $750 USD per bushel by June 2008 and
plummeted to the $370 per bushel by year end1. Farmers are sitting on
inventories and not selling their crops and holding out for better prices.
Management and analysts believe the competition for corn, once viewed as a
commodity and now viewed as a matter of national security for countries, is here
to stay. Though prices have dropped in the last six months of 2008, the price is
still double that of two years ago in January 2006. The use of corn for the
production of ethanol and the agricultural policies of leading petroleum usage
countries continue to exert price and demand pressures on the
market2.

Due to the prolonged high prices of inputs, an upward cycle
which has lasted for two years, and general conditions which are affecting the
business of the company; management has determined to refocus, assess, and
identify alternative business strategies.

Liquidity and Capital Resources

Our cash reserves of $13,224 as at December 31, 2008 ($12,459
as at September 30, 2008) are not sufficient to meet our funding needs beyond
the next nine-month period. To this effect, the company will need to seek
additional funding in the near future. We currently do not have a specific plan
for obtaining

|_______________________________
|-------------------------------
|1                              
|2                              

---

such funding, however, we anticipate that any additional
funding will be in the form of equity financing from the sale of our common
stock and/or loans (interest or convertible). We currently do not have any
arrangements in place for any future equity financing. We may also seek to
obtain short-term loans from our directors, although no such arrangements have
as yet been made. There can be no assurance that we will be able to raise
sufficient funding from the sale of our common stock or through director loans
to meet our funding needs after the next nine months.

The Independent Auditor's Report to our audited financial
statements for the period ended September 30, 2008 indicated that there are a
number of factors that raise substantial doubt about our ability to continue as
a going concern. Such factors identified in the report include that we need to
generate profitable operations and are in need of obtaining adequate financing.
For these and other related reasons our auditors believe that there is
substantial doubt that we will be able to continue as a going concern.

Comparison of Interim Financial Results

As at December 31, 2008, accounts payable balance is $45,950
compared to $46,213 as at September 30, 2008. Loan payable balance is $40,800
compared to $40,000 as at September 30, 2008.

Sales have decreased year over year due to the increasing
prices of maize

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements
that have or are reasonably likely to have a current or future effect on the
small business issuer's financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or
capital resources that is material to investors.

Item 3. Quantitative and Qualitative Disclosures About
Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures. The
Company's Management under the supervision and with the participation of the
Principal Executive Officer and the Principal Financial Officer are responsible
for establishing and maintaining "disclosure controls and procedures" (as
defined in the Exchange Act) for the Company. Based on their evaluation of the
Company's disclosure controls and procedures as of December 31, 2008, the
Company's Management has concluded that the Company's disclosure controls and
procedures were effective to ensure that the information required to be
disclosed by the Company under the Exchange Act was recorded, processed,
summarized and reported within the time periods specified in the Exchange Act
and accumulated and communicated to the Company's Management, including the
Principal Executive Officer and the Principal Financial Officer, to allow timely
decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting.During the fiscal quarter ending December 31, 2008, there were no changes in
the Company's internal control over financial reporting during the period
covered by this report that have materially affected, or are reasonably likely
to materially affect, the Company's internal control over financial
reporting.

Limitations on the Effectiveness of Controls.A control
system, no matter how well conceived and operated, can provide only reasonable,
not absolute, assurance that the objectives of the control system are

---

met. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all
control issues, if any, within a company have been detected. The Company's
disclosure controls and procedures are designed to provide reasonable assurance
of achieving their objectives, and the Principal Executive Officer and the
Principal Financial Officer have concluded that these controls and procedures
are effective at the "reasonable assurance" level.

Item 4T. Controls and Procedures.

The Company's management is responsible for establishing and
maintaining adequate internal control over financial reporting. Our internal
control over financial reporting is designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted
accounting principles.

Our internal control over financial reporting includes those
policies and procedures that:

- Pertain to the maintenance of records that, in reasonable detail,
  accurately and fairly reflect the transactions and dispositions of the assets
  of the Company;
- Provide reasonable assurance that transactions are recorded as necessary to
  permit preparation of financial statements in accordance with generally
  accepted accounting principles, and that receipts and expenditures are being
  made only in accordance with authorizations of management and the director;
  and
- Provide reasonable assurance regarding prevention or timely detection of
  unauthorized acquisition, use or disposition of assets that could have a
  material effect on the financial statements.

As required by Rule 13a-15 and 15d-15 under the Securities and
Exchange Act of 1934, Management assessed the effectiveness of the Companys
internal control over financial reporting as of December 31, 2008. Based on this
assessment, the Company's management has concluded that the Company maintained
effective internal control over financial reporting as of December 31, 2008, the
end of the period covered by this quarterly report.

This quarterly report does not include an attestation report of
the company's registered public accounting firm regarding internal control over
financial reporting. Management's report was not subject to attestation by the
company's registered public accounting firm pursuant to temporary rules of the
Securities and Exchange Commission ("SEC") that permit the Company to provide
only management's report in this quarterly report.

Changes in Internal Control over Financial Reporting.Management has evaluated whether any changes in our internal control over
financial reporting that occurred during our last fiscal quarter have materially
effected, or reasonably likely to materially effect our internal control over
financial reporting. Based on the evaluation we conducted, management has
concluded that during the fiscal quarter ending December 31, 2008, there were no
changes in the Company's internal control over financial reporting during the
period covered by this report that have materially affected, or are reasonably
likely to materially affect, the Company's internal control over financial
reporting.

A control system, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the
control system are met. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all
control issues, if any, within a company have been detected. The Company's
disclosure controls and procedures are designed to provide reasonable assurance
of achieving their objectives, and the Principal Executive Officer and the
Principal

---

Financial Officer have concluded that these controls and
procedures are effective at the "reasonable assurance" level.

PART II  OTHER INFORMATION

Item 1. Legal Proceedings.

We are not currently a party to any legal proceedings.

Item 1A. Risk Factors.

Not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of
Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Submission of Matters to a Vote of Security
Holders.

No matters have been submitted to our security holders for a
vote, through the solicitation of proxies or otherwise, during the quarterly
period ended December 31, 2008.

Item 5. Other Information.

None.

Item 6. Exhibits.

|31.1 | Certification of Principal Executive Officer pursuant to
  Section 302 of the Sarbanes-Oxley Act of 2002.    
|---- | -------------------------------------------------------------------------------------------------------------
|     |                                                                                                              
|31.2 | Certification of Principal Financial Officer pursuant to
      Section 302 of the Sarbanes-Oxley Act of 2002.
|     |                                                                                                              
|32.1 | Certification of Principal Executive Officer pursuant to
      Section 906 of the Sarbanes-Oxley Act of 2002.
|     |                                                                                                              
|32.2 | Certification of Principal Financial Officer pursuant to
      Section 906 of the Sarbanes-Oxley Act of 2002.

---

SIGNATURES

In accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

|      |                   |  | PURE
      PHARMACEUTICALS CORPORATION
|----- | ----------------- |  | --------------------------------------
|      |                   |  | (Registrant)                          
|      |                   |  |                                       
|      |                   |  |                                       
|Date: | February 17, 2009 |  | By:                                   
|      |                   |  |                                       
|      |                   |  |                                       
|      |                   |  |                                       
|      |                   |  |                                       
|      |                   |  |                                       
|Date: | February 17, 2009 |  | By:                                   
|      |                   |  |                                       
|      |                   |  |                                       

---